Banda, Clifford G. http://orcid.org/0000-0002-0757-5259
Chaponda, Mike
Mukaka, Mavuto
Mulenga, Modest
Hachizovu, Sebastian
Kabuya, Jean B.
Mulenga, Joyce
Sikalima, Jay
Kalilani-Phiri, Linda
Terlouw, Dianne J.
Khoo, Saye H.
Lalloo, David G.
Mwapasa, Victor
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and safety of artemether–lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial
https://doi.org/10.1186/s12936-019-2818-7
Efficacy and safety of dihydroartemisinin–piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial
https://doi.org/10.1186/s12936-019-2909-5
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (IP.07.31060.003)
Article History
Received: 11 February 2019
Accepted: 18 May 2019
First Online: 24 May 2019
Ethics approval and consent to participate
: The trial received ethics approval from Tropical Disease Research Centre (TDRC) Ethics Review Committee in Zambia as well as regulatory approval from the Zambia Medicines Regulatory Authority (ZAMRA). Additional, ethics approvals were obtained from collaborating institutions in Malawi (College of Medicine Research and Ethics Committee) and United Kingdom (Liverpool School of Tropical Medicine Research Committee). Written informed consent was sought from all participants aged ≥ 18 years. Assent was sought from those who were aged < 18 years, except for “mature minors”.
: Written informed consent to publish the data was sought from all participants aged ≥ 18 years. Assent was sought from those who were aged < 18 years, except for “mature minors”.
: The authors declare that they have no competing interests.